HCM
LFCR icon

Harspring Capital Management’s Lifecore Biomedical LFCR Stock Holding History

Harspring Capital Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-226,416
Closed -$2.56M – 29
2019
Q4 		$2.56M Buy
+226,416
New +$2.41M 1.66% 19

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
WC
Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return

Harspring Capital Management's LFCR Position: Q1 2020 in Review

Harspring Capital Management sold out of Lifecore Biomedical (LFCR) in Q1 2020, closing a stake of 226,416 shares — an estimated $2.56M sold.

Harspring Capital Management first reported a position in LFCR in Q4 2019 and held it in 1 quarter. The position peaked at $2.56M in Q4 2019. 88 funds tracked by Wall St. Rank hold LFCR as of Q1 2020.

  • Harspring Capital Management reported no remaining Lifecore Biomedical position as of Q1 2020 after selling out during the quarter.
  • Harspring Capital Management sold 226,416 Lifecore Biomedical shares in Q1 2020, an estimated $2.56M.
  • Harspring Capital Management first reported a position in Lifecore Biomedical in Q4 2019 and held it in 1 quarter.
  • Harspring Capital Management's Lifecore Biomedical position peaked at $2.56M in Q4 2019.
  • 88 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2020.

Based on Harspring Capital Management's 13F filing for Q1 2020, filed 12 May 2020.